Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Review Article

Do Drugs Work for ΟΑΒ Following Prostate Cancer Surgery

Author(s): Vasileios Sakalis * and Anastasia Gkotsi

Volume 21 , Issue 15 , 2020

Page: [1515 - 1526] Pages: 12

DOI: 10.2174/1389450121666200716202103

Price: $65

Abstract

There is evidence that post-radical prostatectomy (post-RP) incontinence is not just the insufficiency of the external urethral sphincter mechanism. Up to a third of men with post-RP incontinence suffer from bladder dysfunction, namely overactive bladder (OAB). OAB is a complex symptom syndrome with poorly defined pathophysiology. It causes a significant burden to patients, negatively affects the quality of their life and its management might be difficult and challenging.

The incidence of post-RP OAB ranges from 15.2 to 37.8%. The aetiology is multifactorial and includes the partial decentralization of the bladder, the detrusor underactivity, the bladder outlet obstruction and the co-existence with stress urinary incontinence (SUI). Post-RP SUI may lead to defunctionalized bladder and activation of urethrovesical reflex which further deteriorate post-RP continence. The diagnostic work-up of men with post-RP OAB should aim to identify potential aetiologic factors and personalize the treatment accordingly.

Until now, there is no robust data from literature with regards to post-RP OAB management. It seems that anticholinergics and PDE5 inhibitors are effective in improving OAB parameters.

Keywords: Overactive bladder, urge incontinence, radical prostatectomy, prostate cancer, urgency, mixed incontinence.

Graphical Abstract
[1]
Abrams P, Cardozo L, Fall M, et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21(2): 167-78.
[http://dx.doi.org/10.1002/nau.10052] [PMID: 11857671]
[2]
Abrams P, Cardozo L, Khoury S, Wein A. 5th International consultation on Incontinence 5th Edition 2013.
[3]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[4]
EAU guidelines Edn, Presented at EAU Annual Congress Copenhagen 2018.978-94-92671-01-1
[5]
Eastham JA, Scardino PT, Kattan MW. Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. J Urol 2008; 179(6): 2207-10.
[http://dx.doi.org/10.1016/j.juro.2008.01.106] [PMID: 18423693]
[6]
Patel VR, Sivaraman A, Coelho RF, et al. Pentafecta: a new concept for reporting outcomes of robot-assisted laparoscopic radical prostatectomy. Eur Urol 2011; 59(5): 702-7.
[http://dx.doi.org/10.1016/j.eururo.2011.01.032] [PMID: 21296482]
[7]
Thiruchelvam N, Cruz F, Kirby M, Tubaro A, Chapple CR, Sievert KD. A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment. BJU Int 2015; 116(6): 853-61.
[http://dx.doi.org/10.1111/bju.13078] [PMID: 25684118]
[8]
Coughlin GD, Yaxley JW, Chambers SK, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncol 2018; 19(8): 1051-60.
[http://dx.doi.org/10.1016/S1470-2045(18)30357-7] [PMID: 30017351]
[9]
Haglind E, Carlsson S, Stranne J, et al. LAPPRO steering committee. on behalf of the LAPPRO steering committee. Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: A prospective, controlled, nonrandomised trial. Eur Urol 2015; 68(2): 216-25.
[http://dx.doi.org/10.1016/j.eururo.2015.02.029] [PMID: 25770484]
[10]
Matsukawa Y, Yoshino Y, Ishida S, et al. De novo overactive bladder after robot-assisted laparoscopic radical prostatectomy. Neurourol Urodyn 2018; 37(6): 2008-14.
[http://dx.doi.org/10.1002/nau.23556] [PMID: 29635709]
[11]
Donnellan SM, Duncan HJ, MacGregor RJ, Russell JM. Prospective assessment of incontinence after radical retropubic prostatectomy: objective and subjective analysis. Urology 1997; 49(2): 225-30.
[http://dx.doi.org/10.1016/S0090-4295(96)00451-7] [PMID: 9037284]
[12]
Sacco E, Prayer-Galetti T, Pinto F, et al. Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int 2006; 97(6): 1234-41.
[http://dx.doi.org/10.1111/j.1464-410X.2006.06185.x] [PMID: 16686718]
[13]
Aning JJ, MacKenzie KR, Fabricius M, et al. Detailed analysis of patient-reported lower urinary tract symptoms and effect on quality of life after robotic radical prostatectomy. Urol Oncol 2018; 36(8): 364.e15-22.
[http://dx.doi.org/10.1016/j.urolonc.2018.05.017] [PMID: 29891407]
[14]
Izumi H, Kaiho Y, Miyazato M, Kawamorita N, Nakagawa H, Arai Y. Effects of phosphodiesterase type 5 inhibitor, tadalafil, on continence reflex in rats. Int Urogynecol J Pelvic Floor Dysfunct 2014; 25(12): 1721-7.
[http://dx.doi.org/10.1007/s00192-014-2453-3] [PMID: 24988889]
[15]
Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104(3): 352-60.
[http://dx.doi.org/10.1111/j.1464-410X.2009.08427.x] [PMID: 19281467]
[16]
Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006; 148(5): 565-78.
[http://dx.doi.org/10.1038/sj.bjp.0706780] [PMID: 16751797]
[17]
Porena M, Mearini E, Mearini L, Vianello A, Giannantoni A. Voiding dysfunction after radical retropubic prostatectomy: more than external urethral sphincter deficiency. Eur Urol 2007; 52(1): 38-45.
[http://dx.doi.org/10.1016/j.eururo.2007.03.051] [PMID: 17403565]
[18]
Hennessey DB, Hoag N, Gani J. Impact of bladder dysfunction in the management of post radical prostatectomy stress urinary incontinence-a review. Transl Androl Urol 2017; 6(Suppl. 2): S103-11.
[http://dx.doi.org/10.21037/tau.2017.04.14] [PMID: 28791229]
[19]
Fontaine CL, Rudd I, Pakzad M, Hamid R, Ockrim JL, Greenwell TJ. Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity. Urol Ann 2017; 9(3): 249-52.
[http://dx.doi.org/10.4103/UA.UA_172_16] [PMID: 28794591]
[20]
Moore KN, Truong V, Estey E, Voaklander DC. Urinary incontinence after radical prostatectomy: can men at risk be identified preoperatively? J Wound Ostomy Continence Nurs 2007; 34(3): 270-9.
[http://dx.doi.org/10.1097/01.WON.0000270821.91694.56] [PMID: 17505246]
[21]
Trofimenko V, Myers JB, Brant WO. Post-prostatectomy incontinence: how common and bothersome is it really? Sex Med Rev 2017; 5(4): 536-43.
[http://dx.doi.org/10.1016/j.sxmr.2017.05.001] [PMID: 28642049]
[22]
Groutz A, Blaivas JG, Chaikin DC, Weiss JP, Verhaaren M. The pathophysiology of post-radical prostatectomy incontinence: a clinical and video urodynamic study. J Urol 2000; 163(6): 1767-70.
[http://dx.doi.org/10.1016/S0022-5347(05)67538-6] [PMID: 10799178]
[23]
Thiel DD, Young PR, Broderick GA, et al. Do clinical or urodynamic parameters predict artificial urinary sphincter outcome in post-radical prostatectomy incontinence? Urology 2007; 69(2): 315-9.
[http://dx.doi.org/10.1016/j.urology.2006.10.026] [PMID: 17320671]
[24]
Haga N, Ogawa S, Yabe M, et al. Association between postoperative pelvic anatomic features on magnetic resonance imaging and lower tract urinary symptoms after radical prostatectomy. Urology 2014; 84(3): 642-9.
[http://dx.doi.org/10.1016/j.urology.2014.04.044] [PMID: 25059593]
[25]
Barrington FJF. The component reflexes of micturition in the cats, parts 1 and 2. Brain 1931; 54: 177-88.
[http://dx.doi.org/10.1093/brain/54.2.177]
[26]
Jung SY, Fraser MO, Ozawa H, et al. Urethral afferent nerve activity affects the micturition reflex; implication for the relationship between stress incontinence and detrusor instability. J Urol 1999; 162(1): 204-12.
[http://dx.doi.org/10.1097/00005392-199907000-00069] [PMID: 10379788]
[27]
Shafik A, Shafik AA, El-Sibai O, Ahmed I. Role of positive urethrovesical feedback in vesical evacuation. The concept of a second micturition reflex: the urethrovesical reflex. World J Urol 2003; 21(3): 167-70.
[http://dx.doi.org/10.1007/s00345-003-0340-5] [PMID: 12898170]
[28]
Shafik A, el-Sibai O, Ahmed I. Effect of urethral dilation on vesical motor activity: identification of the urethrovesical reflex and its role in voiding. J Urol 2003; 169(3): 1017-9.
[http://dx.doi.org/10.1097/01.ju.0000046384.71563.51] [PMID: 12576835]
[29]
Hubeaux K, Deffieux X, Desseaux K, Verollet D, Damphousse M, Amarenco G. Stand up urgency: is this symptom related to a urethral mechanism? Prog Urol 2012; 22(8): 475-81.
[http://dx.doi.org/10.1016/j.purol.2012.04.011] [PMID: 22732583]
[30]
Serels SR, Rackley RR, Appell RA. Surgical treatment for stress urinary incontinence associated with valsalva induced detrusor instability. J Urol 2000; 163(3): 884-7.
[http://dx.doi.org/10.1016/S0022-5347(05)67827-5] [PMID: 10688000]
[31]
Bunn F, Kirby M, Pinkney E, et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract 2015; 69(2): 199-217.
[http://dx.doi.org/10.1111/ijcp.12518] [PMID: 25495905]
[32]
Azadzoi KM, Radisavljevic ZM, Golabek T, Yalla SV, Siroky MB. Oxidative modification of mitochondrial integrity and nerve fiber density in the ischemic overactive bladder. J Urol 2010; 183(1): 362-9.
[http://dx.doi.org/10.1016/j.juro.2009.08.103] [PMID: 19914644]
[33]
Peyronnet B, Brucker BM. Management of overactive bladder symptoms after radical prostatectomy. Curr Urol Rep 2018; 19(12): 95.
[http://dx.doi.org/10.1007/s11934-018-0847-3] [PMID: 30306278]
[34]
Vrijens D, Drossaerts J, van Koeveringe G, Van Kerrebroeck P, van Os J, Leue C. Affective symptoms and the overactive bladder - a systematic review. J Psychosom Res 2015; 78(2): 95-108.
[http://dx.doi.org/10.1016/j.jpsychores.2014.11.019] [PMID: 25499886]
[35]
Cunningham KG, Lenaine Westney O. post-prostatectomy bladder dysfunction: Where are we now? Curr Bladder Dysfunct Rep 2016; 11: 325-33.
[http://dx.doi.org/10.1007/s11884-016-0392-1]
[36]
Menon M, Dalela D, Jamil M, et al. Functional recovery, oncologic outcomes and postoperative complications after rodot-assistes radical prostatectomy: An evidence-based analysis comparing the Retzius sparing and standard approached. J Urol 2018; 199(5): 1210-7.
[http://dx.doi.org/10.1016/j.juro.2017.11.115] [PMID: 29225060]
[37]
Heesakkers J, Farag F, Bauer RM, Sandhu J, De Ridder D, Stenzl A. Pathophysiology and contributing factors in postprostatectomy incontinence: a review. Eur Urol 2017; 71(6): 936-44.
[http://dx.doi.org/10.1016/j.eururo.2016.09.031] [PMID: 27720536]
[38]
Milios JE, Ackland TR, Green DJ. Pelvic floor muscle training in radical prostatectomy: a randomized controlled trial of the impacts on pelvic floor muscle function and urinary incontinence. BMC Urol 2019; 19(1): 116.
[http://dx.doi.org/10.1186/s12894-019-0546-5] [PMID: 31729959]
[39]
Ficazzola MA, Nitti VW. The etiology of post-radical prostatectomy incontinence and correlation of symptoms with urodynamic findings. J Urol 1998; 160(4): 1317-20.
[http://dx.doi.org/10.1016/S0022-5347(01)62525-4] [PMID: 9751344]
[40]
Ventimiglia B, Tsirgiotis A, Fanzone I, Coco T, Privitera S. [Urinary incontinence after radical prostatectomy. Neurophysiological and urodynamic diagnosis] Urologia 2011; 78(2): 82-5.
[http://dx.doi.org/10.5301/RU.2011.7975] [PMID: 21553387]
[41]
Leach GE, Trockman B, Wong A, Hamilton J, Haab F, Zimmern PE. Post-prostatectomy incontinence: urodynamic findings and treatment outcomes. J Urol 1996; 155(4): 1256-9.
[http://dx.doi.org/10.1016/S0022-5347(01)66235-9] [PMID: 8632545]
[42]
Giannantoni A, Mearini E, Zucchi A, et al. Bladder and urethral sphincter function after radical retropubic prostatectomy: a prospective long-term study. Eur Urol 2008; 54(3): 657-64.
[http://dx.doi.org/10.1016/j.eururo.2007.10.054] [PMID: 18006215]
[43]
Song C, Lee J, Hong JH, Choo MS, Kim CS, Ahn H. Urodynamic interpretation of changing bladder function and voiding pattern after radical prostatectomy: a long-term follow-up. BJU Int 2010; 106(5): 681-6.
[http://dx.doi.org/10.1111/j.1464-410X.2009.09189.x] [PMID: 20128778]
[44]
Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA/SUFU guideline Amendment 2019. J Urol 2019; 202(3): 558-63.
[http://dx.doi.org/10.1097/JU.0000000000000309] [PMID: 31039103]
[45]
Payne CK. Behavioral therapy for overactive bladder. Urology 2000; 55(5A)(Suppl.): 3-6.
[http://dx.doi.org/10.1016/S0090-4295(99)00484-7] [PMID: 10767442]
[46]
Cardozo LD. Biofeedback in overactive bladder. Urology 2000; 55((5A Suppl)): 24-8.
[47]
Bo K, Fernandes ACNL, Duarte TB, Brito LGO, Ferreira CHJ. Is pelvic floor muscle training effective for symptoms of overactive bladder in women? A systematic review. Physiotherapy 2020; 106: 65-76.
[http://dx.doi.org/10.1016/j.physio.2019.08.011] [PMID: 32026847]
[48]
Burgio KL, Kraus SR, Johnson TM II, et al. Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: A randomized clinical trial. JAMA Intern Med 2020. Epub ahead of print
[http://dx.doi.org/10.1001/jamainternmed.2019.6398] [PMID: 31930360]
[49]
Tienforti D, Sacco E, Marangi F, et al. Efficacy of an assisted low-intensity programme of perioperative pelvic floor muscle training in improving the recovery of continence after radical prostatectomy: a randomized controlled trial. BJU Int 2012; 110(7): 1004-10.
[http://dx.doi.org/10.1111/j.1464-410X.2012.10948.x] [PMID: 22332815]
[50]
Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006; 176(1): 177-85.
[http://dx.doi.org/10.1016/S0022-5347(06)00590-8] [PMID: 16753396]
[51]
Habashy D, Losco G, Tse V, Collins R, Chan L. Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes. BJU Int 2015; 116(Suppl. 3): 61-5.
[http://dx.doi.org/10.1111/bju.13110] [PMID: 26176660]
[52]
Sakalis V, Olive R, Caygill P, Guy P, Davies M. Patient reported outcomes after ileocystoplasty in spinal cord injury population. Neurourol Urodyn 2018; 37: S88-9.
[53]
Ehlert FJ, Griffin MT, Abe DM, et al. The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J Pharmacol Exp Ther 2005; 313(1): 368-78.
[http://dx.doi.org/10.1124/jpet.104.077909] [PMID: 15608083]
[54]
Michel MC, Barendrecht MM. Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol Ther 2008; 117(3): 297-312.
[http://dx.doi.org/10.1016/j.pharmthera.2007.12.001] [PMID: 18221785]
[55]
Yoshida M, Masunaga K, Satoji Y, Maeda Y, Nagata T, Inadome A. Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance. J Pharmacol Sci 2008; 106(2): 193-8.
[http://dx.doi.org/10.1254/jphs.FM0070115] [PMID: 18285653]
[56]
Andersson KE, McCloskey KD. Lamina propria: the functional center of the bladder? Neurourol Urodyn 2014; 33(1): 9-16.
[http://dx.doi.org/10.1002/nau.22465] [PMID: 23847015]
[57]
De Laet K, De Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006; 25(2): 156-61.
[http://dx.doi.org/10.1002/nau.20208] [PMID: 16372316]
[58]
Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169(6): 2253-6.
[http://dx.doi.org/10.1097/01.ju.0000067541.73285.eb] [PMID: 12771763]
[59]
Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54(3): 543-62.
[http://dx.doi.org/10.1016/j.eururo.2008.06.047] [PMID: 18599186]
[60]
Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012; 110(11): 1767-74.
[http://dx.doi.org/10.1111/j.1464-410X.2012.11023.x] [PMID: 22409769]
[61]
Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJC. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012; 18(1)CD005429
[http://dx.doi.org/10.1002/14651858.CD005429.]
[62]
Mitropoulos D, Papadoukakis S, Zervas A, Alamanis C, Giannopoulos A. Efficacy of tolterodine in preventing urge incontinence immediately after prostatectomy. Int Urol Nephrol 2006; 38(2): 263-8.
[http://dx.doi.org/10.1007/s11255-005-4031-6] [PMID: 16868694]
[63]
Liss MA, Morales B, Skarecky D, Ahlering TE. Phase 1 clinical trial of Vesicare™ (solifenacin) in the treatment of urinary incontinence after radical prostatectomy. J Endourol 2014; 28(10): 1241-5.
[http://dx.doi.org/10.1089/end.2014.0342] [PMID: 24924314]
[64]
Bianco FJ, Albala DM, Belkoff LH, et al. A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy. J Urol 2015; 193(4): 1305-10.
[http://dx.doi.org/10.1016/j.juro.2014.09.106] [PMID: 25281778]
[65]
Yang R, Liu L, Li G, Yu J. Efficacy of solifenacin in the prevention of short-term complications after laparoscopic radical prostatectomy. J Int Med Res 2017; 45(6): 2119-27.
[http://dx.doi.org/10.1177/0300060517713405] [PMID: 28661264]
[66]
Shim M, Kim J, Park S, et al. The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study. Urology 2015; 85(5): 1123-9.
[http://dx.doi.org/10.1016/j.urology.2015.01.022] [PMID: 25746580]
[67]
Kleeman FJ. The physiology of the internal urinary sphincter. J Urol 1970; 104(4): 549-54.
[http://dx.doi.org/10.1016/S0022-5347(17)61779-8] [PMID: 5476468]
[68]
Diokno AC, Taub M. Ephedrine in treatment of urinary incontinence. Urology 1975; 5(5): 624-5.
[http://dx.doi.org/10.1016/0090-4295(75)90113-2] [PMID: 1129889]
[69]
Awad SA, Downie JW, Kiruluta HG. Alpha-adrenergic agents in urinary disorders of the proximal urethra. Part I. Sphincteric incontinence. Br J Urol 1978; 50(5): 332-5.
[http://dx.doi.org/10.1111/j.1464-410X.1978.tb03642.x] [PMID: 37972]
[70]
Nito H. Clinical effect of midodrine hydrochloride on the patients with urinary incontinence Hinyokika Kiyo 1994; 40(1): 91-4.
[PMID: 7509120]
[71]
Tsakiris P, de la Rosette JJ, Michel MC, Oelke M. Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence. Eur Urol 2008; 53(1): 53-9.
[http://dx.doi.org/10.1016/j.eururo.2007.09.037] [PMID: 17920183]
[72]
Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of α 1 and β-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003; 170(2 Pt 1): 649-53.
[http://dx.doi.org/10.1097/01.ju.0000067621.62736.7c] [PMID: 12853849]
[73]
Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006; 147(Suppl. 2): S88-S119.
[http://dx.doi.org/10.1038/sj.bjp.0706619] [PMID: 16465187]
[74]
Hudman D, Elliott RA, Norman RIK. K(ATP) channels mediate the beta(2)-adrenoceptor agonist-induced relaxation of rat detrusor muscle. Eur J Pharmacol 2000; 397(1): 169-76.
[http://dx.doi.org/10.1016/S0014-2999(00)00229-6] [PMID: 10844111]
[75]
Yasuda K, Kawabe K, Takimoto Y, Kondo A, Takaki R, Imabayahsi K, et al. Clenbuterol clinical research group. A double-blind clinical trial of a β2-adrenergic agonist in stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1993; 4: 146-51.
[http://dx.doi.org/10.1007/BF00571623]
[76]
Grüneberger A, Geier G. [Treatment of motor urge incontinence with the beta 2-sympathomimetic drug clenbuterol (author’s transl)] Urologe A 1981; 20(3): 153-4.
[PMID: 6115496]
[77]
Noguchi M, Eguchi Y, Ichiki J, Yahara J, Noda S. Therapeutic efficacy of clenbuterol for urinary incontinence after radical prostatectomy. Int J Urol 1997; 4(5): 480-3.
[http://dx.doi.org/10.1111/j.1442-2042.1997.tb00289.x] [PMID: 9354950]
[78]
Zozikov B, Kunchev SI, Varlev C. Application of clenbuterol in the treatment of urinary incontinence. Int Urol Nephrol 2001; 33(3): 413-6.
[http://dx.doi.org/10.1023/A:1019565229886] [PMID: 12230263]
[79]
Silva I, Costa AF, Moreira S, et al. Inhibition of cholinergic neurotransmission by β3-adrenoceptors depends on adenosine release and A1-receptor activation in human and rat urinary bladders. Am J Physiol Renal Physiol 2017; 313(2): F388-403.
[http://dx.doi.org/10.1152/ajprenal.00392.2016] [PMID: 28446460]
[80]
Coelho A, Antunes-Lopes T, Gillespie J, Cruz F. Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study. Neurourol Urodyn 2017; 36(8): 1972-80.
[http://dx.doi.org/10.1002/nau.23224] [PMID: 28185314]
[81]
D’ Agostino G, Maria Condino A, Calvi P. Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor. Eur J Pharmacol 2015; 758: 115-22.
[http://dx.doi.org/10.1016/j.ejphar.2015.03.074] [PMID: 25861936]
[82]
Tubaro A, Batista JE, Nitti VW, et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Ther Adv Urol 2017; 9(6): 137-54.
[http://dx.doi.org/10.1177/1756287217702797] [PMID: 28588652]
[83]
Shin DG, Kim HW, Yoon SJ, et al. Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study. Neurourol Urodyn 2019; 38(1): 295-304.
[http://dx.doi.org/10.1002/nau.23852] [PMID: 30311691]
[84]
Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 2013; 190(4): 1320-7.
[http://dx.doi.org/10.1016/j.juro.2013.05.062] [PMID: 23727415]
[85]
Igawa Y, Aizawa N, Michel MC. β3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions? Br J Pharmacol 2019; 176(14): 2525-38.
[http://dx.doi.org/10.1111/bph.14658] [PMID: 30868554]
[86]
Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 2012; 62(5): 834-40.
[http://dx.doi.org/10.1016/j.eururo.2012.05.053] [PMID: 22695239]
[87]
Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada. Can Urol Assoc J 2015; 9(9-10): 343-50.
[http://dx.doi.org/10.5489/cuaj.3098] [PMID: 26644809]
[88]
Nitti VW, Chapple CR, Walters C, et al. Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. Int J Clin Pract 2014; 68(8): 972-85.
[http://dx.doi.org/10.1111/ijcp.12433] [PMID: 24703195]
[89]
Giuliano F, Ückert S, Maggi M, Birder L, Kissel J, Viktrup L. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013; 63(3): 506-16.
[http://dx.doi.org/10.1016/j.eururo.2012.09.006] [PMID: 23018163]
[90]
Gillespie JI, Markerink-van Ittersum M, de Vente J. Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder. Cell Tissue Res 2005; 321(3): 341-51.
[http://dx.doi.org/10.1007/s00441-005-1151-3] [PMID: 15965654]
[91]
Morelli A, Filippi S, Sandner P, et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 2009; 6(6): 1594-608.
[http://dx.doi.org/10.1111/j.1743-6109.2009.01249.x] [PMID: 19473460]
[92]
Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61(5): 994-1003.
[http://dx.doi.org/10.1016/j.eururo.2012.02.033] [PMID: 22405510]
[93]
Wang Y, Bao Y, Liu J, Duan L, Cui Y. Tadalafil 5mg once daily improves lower urinary tract symptoms and erectile dysfunction: A systematic review and meta-analysis. Low Urin Tract Symptoms 2018; 10(1): 84-92.
[http://dx.doi.org/10.1111/luts.12144] [PMID: 29341503]
[94]
Urakami S, Ogawa K, Oka S, et al. Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α1 -adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: A randomized pilot trial comparing tadalafil and solifenacin. Low Urin Tract Symptoms 2019; 11(3): 109-14.
[http://dx.doi.org/10.1111/luts.12242] [PMID: 30251330]
[95]
Dell’Atti L. Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients. Eur Rev Med Pharmacol Sci 2015; 19(9): 1559-63.
[PMID: 26004592]
[96]
Matsukawa Y, Majima T, Matsuo K, et al. Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study. Int J Urol 2018; 25(3): 246-50.
[http://dx.doi.org/10.1111/iju.13489] [PMID: 29164680]
[97]
Chen H, Wang F, Yu Z, et al. Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized double-blind, placebo-controlled trial. Urology 2017; 100: 59-64.
[http://dx.doi.org/10.1016/j.urology.2016.11.008] [PMID: 27845219]
[98]
Mulhall JP, Brock G, Oelke M, et al. Effects of tadalafil once-daily or on demand vs placebo on return to baseline erectile function after bilateral nerve sparing radical prostatectomy-results from a randomized controlled trial (REACTT). J Sex Med 2016; 13(4): 679-83.
[http://dx.doi.org/10.1016/j.jsxm.2016.01.022] [PMID: 27045264]
[99]
Canat L, Güner B, Gürbüz C, Atış G, Çaşkurlu T. Effects of three-times-per-week versus on-demand tadalafil treatment on erectile function and continence recovery following bilateral nerve sparing radical prostatectomy: results of a prospective, randomized, and single-center study. Kaohsiung J Med Sci 2015; 31(2): 90-5.
[http://dx.doi.org/10.1016/j.kjms.2014.11.005] [PMID: 25645987]
[100]
Gandaglia G, Albersen M, Suardi N, et al. Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy. Int J Urol 2013; 20(4): 413-9.
[http://dx.doi.org/10.1111/j.1442-2042.2012.03149.x] [PMID: 22970988]
[101]
Gacci M, Ierardi A, Rose AD, et al. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. J Sex Med 2010; 7(1 Pt 1): 234-43.
[http://dx.doi.org/10.1111/j.1743-6109.2009.01471.x] [PMID: 19732303]
[102]
Patel HR, Ilo D, Shah N, et al. Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV study. BMC Urol 2015; 15: 31.
[http://dx.doi.org/10.1186/s12894-015-0022-9] [PMID: 25879460]
[103]
Hyndman ME, Bivalacqua TJ, Mettee LZ, Su LM, Trock BJ, Pavlovich CP. Nightly sildenafil use after radical prostatectomy has adverse effects on urinary convalescence: Results from a randomized trial of nightly vs on-demand dosing regimens. Can Urol Assoc J 2015; 9(11-12): 414-9.
[http://dx.doi.org/10.5489/cuaj.3169] [PMID: 26788231]
[104]
Cornu JN, Merlet B, Ciofu C, et al. Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol 2011; 59(1): 148-54.
[http://dx.doi.org/10.1016/j.eururo.2010.10.031] [PMID: 21030144]
[105]
Løvvik A, Müller S, Patel HRH. Pharmacological treatment of post-prostatectomy incontinence:What is the evidence? Drugs Aging 2016; 33(8): 535-44.
[http://dx.doi.org/10.1007/s40266-016-0388-8] [PMID: 27554370]
[106]
Radadia KD, Farber NJ, Shinder B, Polotti CF, Milas LJ, Tunuguntla HSGR. Management of postradical prostatectomy urinary incontinence. Urology 2018; 113: 13-9.
[http://dx.doi.org/10.1016/j.urology.2017.09.025] [PMID: 29031841]
[107]
de Groat WC. Influence of central serotonergic mechanisms on lower urinary tract function. Urology 2002; 59(5)(Suppl. 1): 30-6.
[http://dx.doi.org/10.1016/S0090-4295(01)01636-3] [PMID: 12007520]
[108]
Boy S, Reitz A, Wirth B, et al. Facilitatory neuromodulative effect of duloxetine on pudendal motor neurons controlling the urethral pressure: a functional urodynamic study in healthy women. Eur Urol 2006; 50(1): 119-25.
[http://dx.doi.org/10.1016/j.eururo.2005.12.020] [PMID: 16455184]
[109]
Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995; 274(2): 1014-24.
[PMID: 7636716]
[110]
Klarskov N, Van Till O, Sawyer W, Cernus D, Sawyer W. Effect of a 5-HT2c receptor agonist on urethral closure mechanism in healthy women. Neurourol Urodyn 2019; 38(6): 1700-6.
[http://dx.doi.org/10.1002/nau.24045] [PMID: 31129930]
[111]
FIlocamo MT. Li Marzi V, Del Popolo G, Cecconi F, Villari D, Marzocco M, Nicita G. Pharmacologic treatment in postprostatetomy stress urinary incontinence. Eur Urol 2007; 51(6): 1559-64.
[http://dx.doi.org/10.1016/j.eururo.2006.08.005] [PMID: 16942833]
[112]
Mariappan P, Alhasso A, Ballantyne Z, Grant A, N’Dow J. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol 2007; 51(1): 67-74.
[http://dx.doi.org/10.1016/j.eururo.2006.08.041] [PMID: 17014950]
[113]
Steers WD, Herschorn S, Kreder KJ, et al. Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 2007; 100(2): 337-45.
[http://dx.doi.org/10.1111/j.1464-410X.2007.06980.x] [PMID: 17511767]
[114]
Kornholt J, Sonne DP, Riis T, Sonne J, Klarskov N. Effect of imipramine on urethral opening pressure: A randomized, double-blind, placebo-controlled crossover study in healthy women. Neurourol Urodyn 2019; 38(4): 1076-80.
[http://dx.doi.org/10.1002/nau.23955] [PMID: 30843263]
[115]
Franco I, Arlen AM, Collett-Gardere T, Zelkovic PF. Imipramine for refractory daytime incontinence in the pediatric population J Pediatr Urol 2018; 14(1): 58-e1-5.
[http://dx.doi.org/10.1016/j.jpurol.2017.08.016] [PMID: 29100969]
[116]
Reid GF, Fitzpatrick JM, Worth PH. The treatment of patients with urinary incontinence after prostatectomy. Br J Urol 1980; 52(6): 532-4.
[http://dx.doi.org/10.1111/j.1464-410X.1980.tb03108.x] [PMID: 7459585]
[117]
Gratzke C, Chapple C, Mueller ER, et al. < Robinson D, Rolland C, Staskin D, Stoelzel M, van Maanen R, Siddiqui E. Efficacy and safety of combination pharmacotherapy for patients with overactive bladder: a rapid evidence assessment. Eur Urol 2019; 76(6): 767-79.
[http://dx.doi.org/10.1016/j.eururo.2019.07.010] [PMID: 31416636]
[118]
Yamanishi T, Kaga K, Sakata K, et al. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourol Urodyn 2020; 39(2): 804-12. [epub ahed of print
[http://dx.doi.org/10.1002/nau.24285] [PMID: 31961963]
[119]
Honda M, Kawamoto B, Morizane S, et al. Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study. Scand J Urol 2017; 51(1): 33-7.
[http://dx.doi.org/10.1080/21681805.2016.1250810] [PMID: 27841089]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy